Heart Failure Diagnosis Under the Second Universal Definition

The diagnostic threshold is more explicit

That line on the portal can follow a patient for years. The 2026 consensus update sets a clearer threshold for putting it there: heart failure cannot be inferred from shortness of breath, swelling, an elevated natriuretic peptide concentration, a reduced left ventricular ejection fraction or an abnormal echocardiogram alone. The findings have to fit together as a clinical syndrome.

The framework begins with current or prior symptoms or signs compatible with heart failure. A structural or functional cardiac abnormality must also be present and capable of causing those findings, and objective evidence must support a cardiac explanation. Depending on the setting, that support may come from natriuretic peptide testing, imaging, hemodynamic assessment or evidence of cardiogenic pulmonary or systemic congestion.

The causal link matters. An older adult may have exertional breathlessness and left ventricular hypertrophy, yet those findings do not establish heart failure if lung disease, anemia or deconditioning better accounts for the limitation. The reverse situation also occurs: a patient receiving effective therapy may arrive at an outpatient visit without edema, even though prior symptoms, documented congestion and cardiac dysfunction had already supported the diagnosis.

A portal entry can flatten both situations into the same few words. The definition asks clinicians to preserve the difference.

It also maintains the boundary between heart failure and pre-heart failure. Structural disease, impaired systolic function or elevated filling pressures in someone without symptoms may signal increased risk and justify classification and follow-up. An abnormality by itself does not always amount to the clinical syndrome.

Ejection fraction still matters after heart failure has been established, particularly for phenotype classification and treatment decisions, but it is not a universal diagnostic test. Heart failure can occur with reduced, mildly reduced, preserved or improved ejection fraction. Reduced ejection fraction can also be found before symptoms appear.

How to read evidence that does not line up

The easy case is the textbook presentation, with orthopnea, pulmonary edema, markedly elevated natriuretic peptides, and a clearly abnormal heart. The harder case is common: the symptoms point one way, the scan another, and the blood result seems reassuring until you consider the rest of the clinical context. The consensus favors integration over allowing any single result to operate as an unconditional rule-in or rule-out test.

<table style="min-width: 75px;"><colgroup><col style="min-width: 25px;"><col style="min-width: 25px;"><col style="min-width: 25px;"></colgroup><tbody><tr><th colspan="1" rowspan="1"><p>Clinical pattern</p></th><th colspan="1" rowspan="1"><p>What the definition supports</p></th><th colspan="1" rowspan="1"><p>Documentation approach</p></th></tr><tr><td colspan="1" rowspan="1"><p>Compatible symptoms or signs, a causal cardiac abnormality and objective corroboration</p></td><td colspan="1" rowspan="1"><p>Heart failure is supported when other explanations are less persuasive</p></td><td colspan="1" rowspan="1"><p>Record the syndrome, phenotype and supporting evidence</p></td></tr><tr><td colspan="1" rowspan="1"><p>Symptoms plus abnormal cardiac structure, without a corroborating biomarker or evidence of congestion</p></td><td colspan="1" rowspan="1"><p>Heart failure remains possible, though the evidentiary chain is incomplete</p></td><td colspan="1" rowspan="1"><p>State the uncertainty and pursue testing suited to the clinical context</p></td></tr><tr><td colspan="1" rowspan="1"><p>An objective cardiac abnormality without current or prior symptoms or signs</p></td><td colspan="1" rowspan="1"><p>This may be pre-heart failure rather than clinical heart failure</p></td><td colspan="1" rowspan="1"><p>Describe the abnormality and risk stage without assuming symptomatic disease</p></td></tr><tr><td colspan="1" rowspan="1"><p>Symptoms or congestion without a demonstrated causal cardiac abnormality</p></td><td colspan="1" rowspan="1"><p>A cardiac explanation still needs evaluation</p></td><td colspan="1" rowspan="1"><p>Record the presenting syndrome and the competing diagnoses</p></td></tr><tr><td colspan="1" rowspan="1"><p>Previously established heart failure, now asymptomatic with treatment</p></td><td colspan="1" rowspan="1"><p>The lack of current findings does not erase a substantiated diagnosis</p></td><td colspan="1" rowspan="1"><p>Keep the history and describe the current state</p></td></tr></tbody></table>

Natriuretic peptides show why context cannot be stripped away. Concentrations may be lower than expected in people with obesity and in some presentations of heart failure with preserved ejection fraction. Elevated results have other possible explanations, including atrial fibrillation, kidney dysfunction, advanced age and acute right-heart strain. An isolated peptide result is therefore evidence, not a diagnosis.

Imaging brings similar limits. Left atrial enlargement, ventricular hypertrophy, valvular disease, reduced ejection fraction and abnormal diastolic indices may identify a cardiac substrate, although each finding still needs clinical interpretation. A report that mentions diastolic dysfunction does not establish heart failure with preserved ejection fraction in someone who lacks a compatible syndrome and objective corroboration.

Sometimes congestion supplies the evidence that resting symptoms, peptide testing or standard imaging did not. Clinicians may find support on examination, chest imaging, echocardiography or hemodynamic assessment, including abnormalities that emerge with exercise, and the useful route will depend on how sick the patient is, how likely heart failure already appears and whether another condition explains the presentation better.

This is where the portal line can get ahead of the evidence. A suggestive echocardiogram may be copied into the record as heart failure, even while the clinical question remains open.

What changes for records, coding and clinical decisions

Documentation should reveal the reasoning rather than collect disconnected abnormalities. A useful note describes the symptoms or signs that matter, identifies the cardiac abnormality thought to account for them and points to the objective evidence, while also making room for competing diagnoses and a heart failure phenotype when that phenotype can be assigned with confidence.

The distinction reaches beyond the problem list. Diagnostic language affects quality measurement, risk adjustment, utilization review, epidemiologic surveillance and access to therapies or services. Overcalling heart failure may expose a patient to treatment that is not needed and can distort administrative data. Undercalling it may delay evidence-based care and make the burden of disease look smaller than it is.

For the person reading the portal, none of that machinery is visible. There is just the line.

When evidence remains incomplete, qualified language such as “possible heart failure” or “evaluation for heart failure” may represent the encounter more faithfully than an unqualified diagnosis. Clinicians still have to follow applicable US coding rules, which differ between inpatient and outpatient care and do not always align neatly with consensus terminology.

The definition also guards against removing a supported diagnosis merely because treatment worked. A patient whose ejection fraction improves, natriuretic peptide concentration falls or congestion resolves may have heart failure in remission or heart failure with improved ejection fraction. Those changes describe the current state. They do not show that the earlier syndrome never happened.

This update is a consensus document, not a treatment trial or a comparison of diagnostic strategies. It has no randomized population, effect estimate, confidence interval, p-value or follow-up period. Its contribution is a common framework for deciding when the evidence supports heart failure, when it describes a risk state and when the differential diagnosis remains unsettled.

Where uncertainty remains

Consensus language cannot replace clinical judgment or produce a single threshold that performs the same way in every setting. Natriuretic peptide results shift with age, rhythm, kidney function, body size and acuity. Imaging measurements depend partly on loading conditions and can vary with acquisition and interpretation. Some health systems also have limited access to exercise testing, advanced imaging or invasive hemodynamics.

The framework still needs prospective validation in primary care, emergency care, inpatient practice and specialty settings. Important uncertainty remains for people with obesity or multiple chronic conditions, as well as those with treated disease, intermittent symptoms or suspected heart failure with preserved ejection fraction. Because the document reflects expert consensus rather than comparative outcomes research, it cannot establish that adopting the revised language will improve morbidity, mortality, diagnostic accuracy or resource use.

The uncertainty will not always be visible beside the diagnosis on the portal. It may live only in the note underneath it.

Questions clinicians ask

Does a normal natriuretic peptide result exclude heart failure?

No, not for every patient. A low result reduces the probability, but obesity, treatment and some preserved-ejection-fraction presentations can produce lower concentrations; if substantial clinical suspicion remains, the definition supports looking for other objective evidence instead of allowing one biomarker to settle the case.

Is an abnormal echocardiogram enough to diagnose heart failure?

No. A structural or functional abnormality may provide the cardiac substrate, but clinical heart failure also requires a compatible current or prior syndrome and objective corroboration. In an asymptomatic patient, the more accurate record may describe pre-heart failure or the specific cardiac condition found.

What if symptoms are convincing but resting imaging is inconclusive?

The diagnosis stays unresolved rather than becoming automatically negative. Clinicians can reconsider competing causes and select further objective evaluation, which may include repeat imaging, an exercise-based assessment or hemodynamic testing, according to acuity, pretest probability and what is available locally.

Should heart failure be removed after symptoms and ejection fraction improve?

Not if the original diagnosis was adequately supported. Improvement after therapy describes the patient’s present state and may change the phenotype classification, though it does not erase prior symptoms, cardiac dysfunction or documented congestion. The history remains in the record, and the line on the portal remains beside the current status.

Questions people ask

Does a normal natriuretic peptide result rule out heart failure?

No, a low result reduces the probability but does not exclude heart failure in every patient. Obesity, treatment and some preserved-ejection-fraction presentations can produce lower concentrations, so the story explains why the result must be interpreted with the wider clinical evidence.

Can an abnormal echocardiogram alone confirm heart failure?

No, an abnormal echocardiogram may identify a cardiac problem but does not establish the full syndrome by itself. The update requires compatible current or prior symptoms or signs and objective support for a cardiac explanation. Without symptoms, the finding may be recorded as pre-heart failure or as the specific abnormality.

Should heart failure be removed from the record after symptoms and ejection fraction improve?

Not when the original diagnosis was adequately supported. Improvement may indicate remission or heart failure with improved ejection fraction, but it does not erase the earlier symptoms, dysfunction or documented congestion. The record can preserve the history while describing the current state.

References

1. Second Universal Definition of Heart Failure — PubMed Central, 2026 2. Universal Definition and Classification of Heart Failure — European Journal of Heart Failure, 2021 3. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure — Circulation, 2022 4. 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure — European Heart Journal, 2021